BRCA1 and triple-negative breast carcinoma: Of clinical significance, treatment of human triple negative breast cancer cell lines with vorinostat was able to induce BRCA1 degradation and a subsequent BRCAness phenotype, which synergistically induced cell death in combination with PARPi or cisplatin (102).